Evidence map›Paper›PMID 40403721›Full record

ArticleCell stem cell2025

HBO1 functions as an epigenetic barrier to hepatocyte plasticity and reprogramming during liver injury.

Wei-Chien Yuan, Andrew S Earl, Sai Ma, Karel Alcedo, Jacquelyn O Russell, Fabiana M Duarte, Yen-Ting Chu, Pei-Chi Chang, Hsin-Yi Chen, Hsin-Hui Chi and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell stem cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Wei-Chien YuanStem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Department of Life Sciences and Institute of Genome Sciences, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan; Cancer and Immunology Research Center, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan. Electronic address: wcyuan@nycu.edu.tw.
Andrew S EarlDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Sai MaDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10026 USA.
Karel AlcedoStem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.
Jacquelyn O RussellStem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.
Fabiana M DuarteDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Yen-Ting ChuDepartment of Life Sciences and Institute of Genome Sciences, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
Pei-Chi ChangDepartment of Life Sciences and Institute of Genome Sciences, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
Hsin-Yi ChenInstitute of Biomedical Sciences, Academia Sinica, Taipei 115201, Taiwan.
Hsin-Hui ChiDepartment of Life Sciences and Institute of Genome Sciences, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan; Institute of Biomedical Sciences, Academia Sinica, Taipei 115201, Taiwan.
Qian ZhuDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA; Lester Sue Smith Breast Center, Department of Molecular and Human Genetics, 1 Baylor Plaza, Houston, TX 77030, USA.
Alejo E Rodriguez-FraticelliStem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.
Sachin H PatelStem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.
Yu-Ru LeeInstitute of Biomedical Sciences, Academia Sinica, Taipei 115201, Taiwan.
Jason D BuenrostroDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Fernando D CamargoStem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA. Electronic address: fernando.camargo@childrens.harvard.edu.

Funding

STRUCTURE-FUNCTION RELATIONSHIPS IN THE ALIMENTARY TRACTP30DK034854 · NIDDK · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI JONATHAN C KAGAN · 1986 to 2026
$32.4M
Molecular regulation of native hematopoiesisR01HL128850 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI CAMARGO, FERNANDO · 2016 to 2024
$4.9M
High resolution lineage tracing of developmental hematopoiesisR01HL158192 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI Fernando Camargo, Sahand Hormoz · 2023 to 2026
$3.0M
Hippo signaling and the control of epidermal development and growthR01AR064036 · NIAMS · BOSTON CHILDREN'S HOSPITAL · PI CAMARGO, FERNANDO · 2012 to 2016
$1.9M
Reprogramming of liver cell fate by Hippo signalingR01DK099559 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI CAMARGO, FERNANDO · 2013 to 2017
$1.9M
NHLBI NIH HHS R01 HL128850NHLBI NIH HHS R01 HL158192NIAMS NIH HHS R01 AR064036NIDDK NIH HHS P30 DK034854NIDDK NIH HHS R01 DK099559
6 · The paper itself

Abstract

Hepatocytes can reprogram into biliary epithelial cells (BECs) during liver injury, but the underlying epigenetic mechanisms remain poorly understood. Here, we define the chromatin dynamics of this process using single-cell ATAC-seq and identify YAP/TEAD activation as a key driver of chromatin remodeling. An in vivo CRISPR screen highlights the histone acetyltransferase HBO1 as a critical barrier to reprogramming. HBO1 is recruited by YAP to target loci, where it promotes histone H3 lysine 14 acetylation (H3K14ac) and engages the chromatin reader zinc-finger MYND-type containing 8 (ZMYND8) to suppress YAP/TEAD-driven transcription. Loss of HBO1 accelerates chromatin remodeling, enhances YAP binding, and enables a more complete hepatocyte-to-BEC transition. Our findings position HBO1 as an epigenetic brake that restrains YAP-mediated reprogramming, suggesting that targeting HBO1 may enhance hepatocyte plasticity for liver regeneration.

Indexed as

Cell PlasticityCellular ReprogrammingEpigenesis, GeneticHepatocytesHistone AcetyltransferasesLiverAcetylationAdaptor Proteins, Signal TransducingAnimalsChromatin Assembly and DisassemblyHistonesHumansLiver RegenerationMiceTranscription FactorsYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingHistone AcetyltransferasesHistonesTranscription FactorsYap1 protein, mouseYAP-Signaling Proteinsepigenetic regulationHBO1hepatocyte reprogrammingHippo-YAPin vivo CRISPR screen

Identifiers

PMID40403721
PMCPMC12598758

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.